

Form PTO-1595 (Rev. 08/05)
OMB No. 0651-0027 (exp. 6/30/2008)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Investissement Québec

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) October 5, 2006

- ☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☒ Other Release of Security Agreement

2. Name and address of receiving party(ies)

Name: Ambrilia Biopharma Inc.

Internal Address: _____

Street Address: 1100, chemin du Golf

City: Verdun

State: Québec

Country: Canada Zip: H3E 1H4

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

US 10/902,935

B. Patent No.(s)

6,677,367
6,455,587 6,656,965
6,506,786 6,610,689
6,608,100 6,528,532
6,632,816

Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Philip Swain

Internal Address: _____

Gowling Lafleur Henderson LLP

Street Address: 1, Place Ville Marie

37th Floor

City: Montréal

State: Québec Zip: H3B 3P4

Phone Number: (514) 392-9562

Fax Number: (514) 878-1450

Email Address: philip.swain@gowlings.com

6. Total number of applications and patents involved: 9

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 360.00

- ☐ Authorized to be charged by credit card
☒ Authorized to be charged to deposit account
☐ Enclosed
☐ None required (government interest not affecting title)


8. Payment Information

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number 501644

Authorized User Name Gowlings Ottawa

9. Signature:


Signature
PHILIP SWAIN (Reg. # 55,978)

October 12, 2006

Date

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: 4

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

CH \$360.00 501644 10902935

R E L E A S E

TO: AMBRILIA BIOPHARMA INC.

TO: CANADIAN INTELLECTUAL PROPERTY OFFICE

TO: UNITED STATES PATENT AND TRADEMARK OFFICE

THIS RELEASE, granted on this 5th day of October, 2006, is delivered by **INVESTISSEMENT QUEBEC**, a corporation duly incorporated pursuant to the *Act respecting Investissement Québec and La Financière du Québec* (R.S.Q., c. I-16.1), having its head office at 1200, route de l'Église, Suite 500, Sainte-Foy, Province de Québec G1V 5A3 and having a place of business at 393 St-Jacques Street, Suite 500, Montreal, Province of Quebec, H2Y 1N9 ("IQ"), under a Deed of Movable Hypothec referred to below, herein represented by Marc Langlois as hereby certified by signing this Release;

WHEREAS, AMBRILIA BIOPHARMA INC. (formerly known as Procyon Biopharma Inc.), a corporation incorporated under the laws of Canada, having its head office at 1100, Chemin du Golf, Verdun, Province of Quebec ("Ambrilia") entered into a General and Specific Movable Hypothec Agreement with IQ, dated the 8th day of April 2003 and a First Amendment to the General and Specific Movable Hypothec Agreement dated December 2, 2004 (hereinafter collectively referred to as "**Deed of Movable Hypothec**"), pursuant to which Ambrilia granted to IQ hypothecary rights in, among other things, the patents set forth in Schedule "A" hereto (the "**Released Patents**");

WHEREAS, the Deed of Movable Hypothec was recorded with (a) the Canadian Intellectual Property Office on the 4th day of February 2005, under No. 05306249, and (b) the United States Patent and Trademark Office on the 17th day of December 2004, the 21st day of January 2005, and the 28th day of July 2005, respectively at Reel/Frame Nos. 015469/0488, 015612/0195 and 016930/0828;

WHEREAS, IQ wishes to release all of its hypothecary and other rights in the Released Patents; and

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, IQ hereby releases all of its hypothecary and other rights in the Released Patents, and discharges, quit claims and relinquishes unto Ambrilia (in each case, without recourse and without any representation or warranty) any and all rights, title and interest it has in and to the Released Patents, and more particularly hereby releases the hypothecary rights granted to IQ under the Deed of Movable Hypothec in the Released Patents.

[Signature page follows]

PATENT

IN WITNESS WHEREOF, the undersigned has executed and delivered this Release on the date first written above.

INVESTISSEMENT QUÉBEC



By: _____

Name: Marc Langlois

Title: Directeur Régional, Direction
Régionale de l'Île de Montréal

PATENT

REEL: 018385 FRAME: 0525

SCHEDULE "A" **LIST OF PATENTS**

1. CANADA

FILE	APP. NO.	ISS. NO.
Amino Acid Derivatives as HIV Aspartyl Protease Inhibitors	2,401,821	
HIV Protease Inhibitors Based on Amino Acid Derivatives	2,440,931	
Urea Derivatives as HIV Aspartyl Protease Inhibitors	2,374,362	
Aromatic Derivatives as HIV Protease Inhibitors	2,435,908	

2. UNITED STATES

FILE	APP. NO.	ISSUANCE NO.
Amino Acid Derivatives as HIV Aspartyl Protease Inhibitors		6,455,587
HIV Protease Inhibitors Based on Amino Acid Derivatives		6,506,736
HIV Protease Inhibitors Based on Amino Acid Derivatives		6,608,100
HIV Protease Inhibitors Based on Amino Acid Derivatives		6,677,367
HIV Protease Inhibitors Based on Amino Acid Derivatives		6,656,965
HIV Protease Inhibitors Based on Amino Acid Derivatives		6,610,689
Urea Derivatives as HIV Aspartyl Protease Inhibitors		6,528,532
Aromatic Derivatives as HIV Protease Inhibitors		6,632,816
Lysine Based Compounds	10/902,935	

PATENT